MiMedx Group, Inc.MDXGNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank64
3Y CAGR-7.1%
5Y CAGR+34.0%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-7.1%/yr
Annual compound
5Y CAGR
+34.0%/yr
Recent deceleration
Percentile
P64
Within normal range
vs 5Y Ago
4.3x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202522.33%
2024-2.56%
2023-0.28%
202227.88%
2021-15.22%
20205.16%
2019-29.34%
2018-11.93%
201724.82%
201670.46%